MYLOTARG is a CD33-directed antibody-drug conjugate indicated for: treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults. treatment of relapsed or refractory CD33-positive AML in adults and in pediatric patients 2 years and older
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of MYLOTARG (gemtuzumab ozogamicin) for injection brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the MYLOTARG (gemtuzumab ozogamicin) for injection tablets cost price in India.
The order for MYLOTARG (gemtuzumab ozogamicin) for injection will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Gemtuzumab is a monoclonal antibody to CD33 linked to a cytotoxic agent from the class of calicheamicins. CD33 is expressed in most leukemic blast cells but also in normal hematopoietic cells, the intensity diminishing with maturation of stem cells..
MYLOTARG (gemtuzumab ozogamicin) for injection, for intravenous use Initial U.S. Approval: 2000
Generic Name: gemtuzumab ozogamicin
For Injection: 4.5 mg as a lyophilized cake or powder in a single-dose vial for reconstitution and dilution
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand MYLOTARG (gemtuzumab ozogamicin) for injection on prescription and Import License in Patient's Name only.
For overseas patients, MYLOTARG (gemtuzumab ozogamicin) for injection can be made available in Send your enquiry to find MYLOTARG (gemtuzumab ozogamicin) for injection in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For MYLOTARG (gemtuzumab ozogamicin) for injection Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
Takeda says cancer drug Alunbrig shows longer benefit vs crizotinib For More Details
Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (gemtuzumab ozogamicin) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up For More Details